Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Receivables (2023 - 2025)

Ascentage Pharma Group International posted quarterly Receivables of $35.9 million for Q4 2025, up 188.58% year-on-year from $12.4 million in Q4 2024, and up 231.07% on a QoQ basis from $10.8 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Receivables data on file, last reported at $35.9 million in Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 188.58% year-over-year to $35.9 million; the trailing twelve-month figure through Dec 2025 stood at $35.9 million (up 188.58% YoY), and the FY2025 full-year result was $35.4 million, up 184.81% from the prior year.
  • Receivables for Q4 2025 stood at $35.9 million, up from $10.8 million in the prior quarter.
  • Across five years, Receivables topped out at $35.9 million in Q4 2025 and bottomed at $10.8 million in Q2 2025.
  • The 3-year median for Receivables is $16.8 million (2024), against an average of $20.1 million.
  • The widest annual swing landed in 2024, when Receivables sank 41.33%; it then jumped 188.58% in 2025.
  • A 3-year view of Receivables shows it stood at $21.2 million in 2023, then tumbled by 41.33% to $12.4 million in 2024, then soared by 188.58% to $35.9 million in 2025.
  • The last three Receivables figures came in at $35.9 million (Q4 2025), $10.8 million (Q2 2025), and $12.4 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 13.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - 4.97 Mn
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 2.00 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 5.73 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 883.96 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 35.87 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 35.87 Mn
Jun 30, 2025 10.83 Mn
Dec 31, 2024 12.43 Mn
Dec 31, 2023 21.18 Mn